Chitosan Biomaterials Patents: Who Leads, Where Gaps Are 2026
- 7,721 patent families span the field, but co-assignee pairs number only 10 — ownership is a long tail, not a concentrated few.
- Filings peaked in 2025 at 508 after sitting flat near 357 at the 2022 midpoint, a plateau rather than accelerating growth.
- Cosmetics and microbial-engineering uses trail badly at 448 and 410 records against a 4,654-record medicinal-preparations core — the clearest under-claimed branches.
Filing growth compares 2021 (318 records) with 2024 (459) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 7,721 records in scope (CR5), not by the ranked leaders only.
Where chitosan biomaterial claims concentrate
Chitosan’s patent activity clusters where the polymer’s biocompatibility and biodegradability translate directly into a therapeutic or wound-care claim. Medicinal preparations (A61K) and polysaccharide chemistry (C08B) together account for the majority of the corpus, with sterilising and disinfecting applications — largely wound dressings and antibacterial coatings — forming the third-largest block. Degree of deacetylation and crosslinking method are the two technical levers that show up repeatedly across the highest-cited filings, since both control the mechanical and drug-release properties that downstream medical and cosmetic uses depend on.
The receiving-office spread — led by China, then the United States, EPO, India, WIPO and Japan — points to a field being prosecuted broadly rather than concentrated in one jurisdiction, consistent with chitosan's use across low-cost commodity wound care as well as higher-value drug-delivery formulations.
Filing trends and technology composition
Filing activity across chitosan biomaterials and hydrogels has cooled from its 2025 peak, and the IPC spread shows where the claim density actually sits.
Filings 2017-2026: flat-to-declining after a 2025 peak
Filings rose from 346 in 2017 to a peak of 508 in 2025, with 2022 sitting at 357 roughly at the midpoint — the growth curve is flat rather than accelerating, and 2026's 190 is a partial year understated by the usual 18-month publication lag.
Medicinal preparations and polysaccharide chemistry dominate
A61K (medicinal preparations) leads with 4,654 records, followed by C08B (polysaccharides) at 3,214 and A61L (sterilising/disinfecting, largely wound care) at 2,467 — cosmetics (A61Q, 448) and microorganism engineering (C12N, 410) trail well behind, marking the thinner branches of the field.
Shares are the percentage of the 7,721 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Chitosan Biomaterials and Hydrogels with Eureka
This page is one run against one query. Ask Eureka your own question about chitosan biomaterials and hydrogels and every answer comes back with the patent numbers behind it.
Try EurekaKey patents shaping the field
Visible light-curable water-soluble chitosan derivative, chitosan hydrogel, and preparation method therefor
A visible light-curable glycol chitosan derivative, cured by light in the visible range, forms a hydrogel with wound-healing activity on its own; combined with growth factors, the crosslinked hydrogel shows an enhanced wound-healing effect while the visible-light cure step avoids the drug and growth-factor denaturation that other crosslinking methods can cause.Filed by The Catholic University of Korea Industry-Academic Cooperation Foundation, published 2020-10-15.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US7371403B2 | Wound dressing and method for controlling severe, life-threatening bleeding | 1,138 |
| 2 | US6124273A | Chitin hydrogels, methods of their production and use | 432 |
| 3 | WO1999027960A1 | Vaccine compositions for mucosal administration comprising chitosan | 430 |
| 4 | US4326532A | Antithrombogenic articles | 331 |
| 5 | US5217720A | Coated solid medicament form having releasability in large intestine | 298 |
| 6 | US5629011A | Composition for nasal administration | 252 |
| 7 | US6534091B1 | Microcapsules | 237 |
| 8 | US6602952B1 | Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers | 223 |
| 9 | US5830493A | Bone-forming graft | 216 |
| 10 | US6451337B1 | Chitosan-based nitric oxide donor compositions | 206 |
Ranked by citation count within this corpus; older filings accumulate citations simply by having more years in circulation, so treat rank as a measure of influence rather than current commercial share.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing data actually signals
Three patterns stand out once family counts, citation depth and IPC spread are read together: a plateaued filing curve, a citation record dominated by older hemostatic and hydrogel-production art, and a technology mix skewed hard toward medicinal use over cosmetic or microbial applications.
Growth has flattened, not accelerated
From 346 filings in 2017 to a 2022 midpoint of 357, then up to a 2025 peak of 508, the curve reads as a slow build rather than a rush. 2026's 190 is a partial year and will revise upward as publications catch up.
Older hemostatic art still anchors the field
US7371403B2's wound-dressing mechanism sits far ahead of the next most-cited documents, a gap that reflects years of accumulated reference rather than current commercial weight alone.
Medicinal use dwarfs cosmetic and microbial branches
Medicinal preparations (A61K) outnumber cosmetics use (A61Q) by more than tenfold, and microorganism engineering (C12N) sits similarly thin at 410 records.
A long tail, not a concentrated core
With only 10 recorded co-assignee pairings across the full family count, and most named assignees showing zero filings in the latest year, ownership is dispersed across many single-filing entrants rather than a handful of repeat portfolio builders.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to chitosan biomaterials and hydrogels, with the prior art for and against each one.
Who is filing, and where the activity sits
Ownership in this field is dispersed: a handful of academic institutions show recent-year filing bursts, but the co-assignee network is thin and most named assignees have gone quiet in the latest year.
One institutional filer is accelerating from a low base
Saveetha Institute of Medical & Technical Sciences moved to 27 filings in the latest year, the clearest upward momentum signal in the dataset, though it starts from a small prior base.
A small, tight collaboration cluster around Indian institutions
The strongest co-assignee links — Vanangamudi Sulur Subramaniam, Srinivasan Madhavan and Chulliel Neelakandan Narayanan — each pair at 58 shared filings, forming a dense but narrow cluster rather than a broad alliance network; none of the three shows filings in the latest year.
Mostly single-filer activity, not portfolio consolidation
With only 10 recorded co-assignee pairings against the full family count, most chitosan biomaterial patents originate from single, independent applicants rather than joint corporate-academic programmes.
| Assignee | Recent year | YoY |
|---|---|---|
| SAVEETHA INST OF MEDICAL & TECH SCI | 27 | +108% |
| VANANGAMUDI SULUR SUBRAMANIAM | 0 | — |
| Engenui SA | 0 | -100% |
| Archimedes Development Ltd | 0 | — |
| Medical Industry Products Ltd | 0 | — |
| Centre National de la Recherche Scientifique (CNRS) | 0 | -100% |
| CHULLIEL NEELAKANDAN NARAYANAN | 0 | — |
| SRINIVASAN MADHAVAN | 0 | — |
Where to take this analysis next
The filing and citation patterns above point to specific follow-up work rather than a single conclusion.
Check freedom-to-operate against the top-cited filings
US7371403B2 and US6124273A anchor the highest-citation prior art in hemostatic dressings and chitin hydrogel production; any new wound-care or hydrogel filing should be checked against their specific claim mechanisms before committing to a formulation.
Run a claim comparison in EurekaTrack the Saveetha momentum signal
A 108% year-on-year jump from one institutional filer is worth monitoring for follow-on filings that could extend or narrow the claim scope in its area of activity.
Set up assignee monitoring in EurekaScope a first claim in an under-claimed branch
Cosmetics use and microbial co-production sit well below the medicinal-preparations core in filing density; a narrowly specified claim there faces less crowded prior art than a general chitosan composition claim.
Draft and search a claim in EurekaFrequently asked questions
Not in a straightforward upward sense. Filings grew from 346 in 2017 to a peak of 508 in 2025, but the 2022 midpoint of 357 shows the growth was flat for years before that peak, and 2026 volumes will look understated for a while yet because publication typically lags filing by about 18 months. Treat the recent plateau as evidence of a maturing claim landscape rather than a shrinking one — filers are consolidating around known formulations instead of opening new ground as fast as before.
A61L (sterilising and disinfecting, 2,467 records) is the classification most associated with wound-dressing and antibacterial chitosan work, while A61K (medicinal preparations, 4,654 records) covers the broader drug-delivery and formulation side. C08B (polysaccharides, 3,214 records) is where the underlying chitosan chemistry and derivatization claims sit. Anyone filing a wound-care hydrogel should expect to search across all three, since claims often straddle the chemistry-to-application boundary.
The most-cited record in this dataset is US7371403B2, a hemostatic wound dressing patent cited 1,138 times, well ahead of the next most-cited documents such as US6124273A on chitin hydrogel production (432 citations) and WO1999027960A1 on chitosan mucosal vaccine compositions (430 citations). High citation counts inside a searched corpus tend to favour older filings simply because they've had more years to accumulate references, so read these as markers of foundational influence rather than current commercial dominance.
The IPC composition shows cosmetics use (A61Q, 448 records) and microorganism/genetic-engineering integration (C12N, 410 records) are the smallest branches relative to the 4,654-record medicinal preparations core, suggesting these areas are comparatively under-claimed. That does not guarantee an easy filing — it means fewer prior documents to design around, not zero prior art. A narrowly specified derivative and crosslinker combination targeted at one of these smaller branches is a more realistic first claim than a broad chitosan composition claim in the crowded A61K space.
The assignee ranking runs across 7,721 total patent families with only 10 recorded co-assignee pairs, and recent-year momentum data shows most named assignees at zero filings in the latest year — a pattern consistent with a long tail of single-filing entrants rather than a small group of dominant portfolio holders. A handful of academic and institutional filers show short bursts of activity (one shows a 108% year-on-year jump from a low base) rather than sustained multi-year dominance. This spread matters for freedom-to-operate work: there is no single gatekeeper whose portfolio blocks the whole field.
Research Chitosan Biomaterials and Hydrogels in depth with Eureka
Go past this page: query the whole chitosan biomaterials and hydrogels corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.